A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study of LY4100511 (DC-853) for the Treatment of Adult Participants With Moderate-to Severe Plaque Psoriasis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study of LY4100511 (DC-853) for the Treatment of Adult Participants With Moderate-to Severe Plaque Psoriasis
The main purpose of this study is to assess the safety and efficacy of LY4100511 in adult participants with moderate-to-severe plaque psoriasis.
Inclusion Criteria:
Exclusion Criteria:
Augsburg, Bavaria 86150, Germany
Sakai-shi, Osaka 593-8324, Japan
Shinjuku-ku, Tokyo 160-0023, Japan
Wroclaw, Lower Silesian Voivodeship 50-381, Poland
Wroclaw, Lower Silesian Voivodeship 50-566, Poland
Rzeszów, Podkarpackie Voivodeship 35-055, Poland
Gdansk, Pomeranian Voivodeship 80-382, Poland
Szczecin, West Pomeranian Voivodeship 70-332, Poland